The market size of the US life science tools is estimated to be USD 50.01 billion in 2025, and it will grow by USD 62.58 billion in 2026 to about USD 187.03 billion by 2035 with a CAGR of 14.1% between 2026 and 2035.
US Life Science Tools Market Revenue and Trends
The US market for life science tools provides essential laboratory instruments, consumables, reagents, software, and services—including next-generation sequencing platforms, PCR/qPCR systems, mass spectrometers, flow cytometers, microscopes, centrifuges, electrophoresis equipment, antibodies, cell culture media, CRISPR reagents, bioinformatics tools, and automation systems—used by academic institutions, pharmaceutical/biotech companies, CROs, and clinical diagnostic labs for basic research, drug discovery, development, genomics, proteomics, cell biology, and translational medicine.
The US life science tools market is growing rapidly due to increased R&D spending by pharma and biotech, rising investment in precision medicine and cell/gene therapy, growing adoption of multi-omics and high-throughput technologies, expansion of academic and government research funding, and advancements in automation, single-cell analysis, spatial biology, and AI-integrated workflows in life sciences ecosystems.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the US life science tools market?
The increased number of drug discovery pipelines, especially in the fields of oncology, rare diseases, immunology, and neurodegenerative diseases, has increased the need for life science tools combined with the high rate of cell/gene therapy and mRNA-based modality development. As increasing numbers of therapies are advanced to the clinical stages and demand more sophisticated characterization, an increasing number of companies and research centers will demand high-sensitivity, scalable, and reproducible solutions to shorten timelines and enhance the quality of the data.
The technological revolution has brought novel technologies, such as spatial transcriptomics stages, single-cell multi-omics, ultra-high-resolution mass spectrometry, automated liquid handling with AI-driven experiment design, CRISPR screening libraries with higher editing efficiency, and cloud-based bioinformatics suites with increased throughput, resolution, and insight generation. Additional reasons are the presence of strong NIH and other private foundation funding, rising outsourcing to CROs/CDMOs, rising demand on tools to support regulatory-grade data (GLP/GMP), FDA focus on biomarker-driven development, and heavy venture capital investment in next-generation life science startups.
Segment Insight
By Product Type
Next-generation sequencing (NGS) tools and consumables by product are by far the most prevalent tools in life science in the US market as of 2025, owing to high demand in genomics research, oncology biomarker discovery, rare disease diagnostics, and cell/gene therapy characterization due to their high-throughput and cost-effective sequences and the ongoing innovation in long-read sequencing, spatial transcriptomics integration, and ultra-low-input library preparation of increasingly complex biological insights and faster therapeutic development.
By Distribution Channel
The largest market share exists amongst direct sales from instrument vendors and specialized life science distributors to pharmaceutical/biotech companies, academic research institutions, and CROs, which serve as primary channels for procurement of high-end instruments, reagents, consumables, software licenses, and application/technical support. Since these channels provide professional expertise for method development, instrument qualification, training, and regulatory compliance support, they have become preferred options for sourcing life science tools.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 62.58 billion |
Projected Market Size in 2035 | USD 187.03 billion |
Market Size in 2025 | USD 50.01 billion |
CAGR Growth Rate | 14.1% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Product, Technology, Application, End User and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In December 2025: 10x Genomics released its Xenium In Situ platform with increased gene panel capabilities and higher spatial resolution, making it possible to do high-throughput multi-modal spatial transcriptomics and proteomics in FFPE tissues, much enhancing oncology and neuroscience discovery programs in US academic and biotech laboratories.
List of the prominent players in the US Life Science Tools Market:
Thermo Fisher Scientific Inc.
Danaher Corporation
Agilent Technologies Inc.
Illumina Inc.
Bio-Rad Laboratories Inc.
Merck KGaA
QIAGEN N.V.
Becton Dickinson and Company
PerkinElmer Inc.
Waters Corporation
Others
The US Life Science Tools Market is segmented as follows:
By Product
Instruments
o Spectrophotometers
o Chromatography Systems
o Flow Cytometers
o Next-Generation Sequencers
o Mass Spectrometers
o Microscopes
Consumables
o Reagents
o Assay Kits
o Cell Culture Media
o Antibodies
o Microplates
Software & Services
o Data Analysis Software
o Laboratory Information Management Systems
o Assay Development Services
o Contract Research Services
By Technology
Genomics
o Next-Generation Sequencing
o PCR & qPCR
o Microarrays
Proteomics
o Mass Spectrometry
o Protein Microarrays
o Chromatography
Cell Biology
o Cell Culture Systems
o Flow Cytometry
o High-Content Screening
Other Technologies
By Application
Drug Discovery & Development
Clinical Diagnostics
Academic Research
Other Applications
By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Healthcare Organizations
